10-Q: Lifeward (ReWalk Robotics) Reports Strong Revenue Growth in Q2 2024 Following AlterG Acquisition and Medicare Expansion

Lifeward, formerly ReWalk Robotics, saw a significant increase in revenue in the second quarter of 2024, driven by the acquisition of AlterG and expanded Medicare coverage for its ReWalk Personal Exoskeleton.

Summary

• Lifeward, previously known as ReWalk Robotics, reported a net loss of $4.3 million for the three months ended June 30, 2024, and a net loss of $10.6 million for the six months ended June 30, 2024.
• The company's revenue for the three months ended June 30, 2024, was $6.7 million, a substantial increase from $1.3 million in the same period of 2023.
• Revenue for the six months ended June 30, 2024, reached $11.99 million, compared to $2.57 million for the same period in 2023.
• The increase in revenue is primarily attributed to the acquisition of AlterG and higher sales of ReWalk Personal exoskeletons due to expanded Medicare coverage.
• Gross profit for the three months ended June 30, 2024, was $2.76 million, compared to $0.58 million in 2023, while gross profit for the six months ended June 30, 2024, was $4.15 million, compared to $1.15 million in 2023.
• Operating expenses for the three months ended June 30, 2024, totaled $7.2 million, and $15.1 million for the six months ended June 30, 2024.
• The company's cash and cash equivalents as of June 30, 2024, were $15.1 million, with a negative operating cash flow of $13.3 million for the six months ended June 30, 2024.
• Lifeward has sufficient funds to support operations for more than 12 months following the issuance date of the financial statements.

Sentiment

Score: 7

Explanation: The document shows strong revenue growth and positive developments with Medicare coverage and new product launches, but also highlights significant losses and cash burn, leading to a moderately positive sentiment.

Positives

• The company experienced a significant increase in revenue due to the AlterG acquisition and expanded Medicare coverage.
• Gross profit margins improved in Q2 2024 compared to Q2 2023, excluding the impact of amortization of intangible assets.
• Lifeward has sufficient funds to support operations for more than 12 months.
• The company successfully launched a new product line and submitted a 510(k) for a next-generation exoskeleton.

Negatives

• The company reported a net loss of $4.3 million for Q2 2024 and $10.6 million for the first half of 2024.
• Operating expenses increased significantly due to the AlterG acquisition and higher promotional spending.
• The company experienced negative operating cash flow of $13.3 million for the first half of 2024.
• Gross profit margins declined in the first half of 2024 compared to the same period in 2023, primarily due to low AlterG product sales in the first quarter.

Risks

• The company is dependent on the successful development and commercialization of its products to achieve profitability.
• Lifeward may need to raise additional capital through private or public offerings, which may not be available on acceptable terms.
• The company faces risks related to activist shareholder activities, including potential litigation.
• The company's future performance is subject to market conditions, including inflation and global instability.
• The company is subject to risks related to the ongoing war between Israel and Hamas and increasing tensions between China and Taiwan.

Future Outlook

The company expects future growth to be driven by sales of the ReWalk Personal device through expanded coverage and reimbursement, as well as sales of AlterG anti-gravity systems and distributed products. Lifeward also intends to focus on advancing product development for its AlterG systems and preparing for the next stages following the recent FDA 510(k) submission for the ReWalk 7.

Management Comments

• The CMS Home Health Rule and Medicare Pricing achieved by Lifeward is now fully functional with widespread approvals and the beginning of payments from our 2023 and first-half 2024 submissions.
• With the experience of access for Medicare beneficiaries, physicians are now able to actively write prescriptions with confidence that on-label SCI individuals have access to this innovative walking and stair climbing technology.
• In June, Lifeward successfully launched the latest generation of Differential Air Pressure Anti-Gravity Technology with its new NEO product line.
• In June, Lifeward completed its FDA submission for its 7th generation ReWalk design which will further enhance use of the system in all aspects of daily life and further establish Lifeward as the most experienced personal exoskeleton company in the world.

Industry Context

The announcement reflects a growing trend in the medical device industry towards innovative rehabilitation technologies and the increasing importance of securing reimbursement from third-party payors, particularly Medicare. The acquisition of AlterG positions Lifeward as a more diversified player in the rehabilitation market, while the expansion of Medicare coverage for exoskeletons is a significant development for the industry.

Comparison to Industry Standards

• The company's revenue growth in Q2 2024 is significantly higher than the industry average for medical device companies, primarily due to the acquisition of AlterG and the expansion of Medicare coverage.
• The company's gross profit margin of 41.1% for Q2 2024 is within the typical range for medical device companies, but the decline in gross profit margin for the first half of 2024 indicates a need for improved cost management.
• The company's operating expenses are higher than industry averages, reflecting the costs associated with the AlterG acquisition and the company's focus on research and development.
• The company's negative operating cash flow is a concern, but it is not uncommon for companies in the medical device industry that are in the growth phase.
• The company's success in securing Medicare coverage for its ReWalk Personal Exoskeleton is a significant achievement, as it opens up a large market opportunity for the company.
• The company's submission of a 510(k) premarket notification for the ReWalk 7 Personal Exoskeleton device is a positive sign of its commitment to innovation and product development.
• The company's launch of the new NEO product line of Differential Air Pressure Anti-Gravity Technology is a positive step towards expanding its product portfolio and market reach.

Management Changes

Legal Proceedings

• The company is involved in litigation with Creative Value Capital Limited Partnership regarding the agenda of the company's Annual Meeting.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and potential capital raises.
• Employees may be impacted by changes in the company's structure and operations following the AlterG acquisition.
• Customers may benefit from the company's expanded product offerings and improved access to reimbursement.
• Suppliers may be impacted by changes in the company's purchasing patterns and supply chain.

Next Steps

• The company will focus on driving growth in its commercial product portfolio.
• The company will expand reimbursement coverage by commercial payors for the ReWalk Personal Exoskeleton device.
• The company will integrate and unify the combined sales and marketing resources of the ReWalk and AlterG organizations.
• The company will continue to advance product development for its AlterG Anti-Gravity systems.
• The company will prepare for the next stages following the recent FDA 510(k) submission for clearance of the ReWalk 7 next-generation exoskeleton model.

Key Dates

Keywords

exoskeleton, rehabilitation, medical devices, Medicare, AlterG, ReWalk, revenue growth, spinal cord injury, stroke, physical therapy